Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
| Professional Services Industry | Industrials Sector | Prahlad R. Singh CEO | XBER Exchange | US7140461093 ISIN |
| US Country | 11,000 Employees | 17 Apr 2026 Last Dividend | 4 Jun 2001 Last Split | - IPO Date |
Revvity, Inc., previously known as PerkinElmer, Inc., marks a significant name in the health sciences industry, offering comprehensive solutions, technologies, and services across the globe, including the Americas, Europe, Asia, and other international territories. With its inception in 1937 and headquarters in Waltham, Massachusetts, Revvity has grown to serve an expansive range of clients, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. Operating through two main segments - Life Sciences and Diagnostics - Revvity, Inc. brings forward a suite of instruments, reagents, informatics, software, and much more, catering to a wide array of testing, screening, and research needs in the health sciences sector.
Revvity, Inc.'s product portfolio and services are vast, covering various needs within the life sciences and diagnostics fields. Here's an overview of their most notable offerings: